Replication-Defective Mutants of Herpes Simplex Virus (HSV) Induce Cellular Immunity and Protect against Lethal HSV Infection

LIEN H. NGUYEN, DAVID M. KNIPE, AND ROBERT W. FINBERG

Laboratory of Infectious Diseases, Dana-Farber Cancer Institute, and Department of Microbiology and Molecular Genetics, Harvard Medical School, Boston, Massachusetts 02115

Received 17 April 1992/Accepted 4 September 1992

Live viruses and live virus vaccines induce cellular immunity more readily than do inactivated viruses or purified proteins, but the mechanism by which this process occurs is unknown. A trivial explanation would relate to the ability of live viruses to spread and infect more cells than can inactivated virus. We have used live but replication-defective mutants to investigate this question. Our studies indicate that the immune responses of mice to live virus differ greatly from the responses to inactivated virus even when the virus does not complete a replicative cycle. Further, these studies indicate that herpes simplex virus-specific T-cell responses can be generated by infection with replication-defective mutant viruses. These data indicate that the magnitude of the cellular immunity to herpes simplex virus may be proportional to the number or quantity of different viral gene products expressed by an immunizing virus.

Because herpes simplex viruses (HSV) are ubiquitous human pathogens which cause infections in newborn and immunocompromised patients and considerable morbidity in otherwise healthy people, considerable efforts have gone into producing herpesvirus-specific vaccines (2, 7, 20, 31, 39, 43-46). Although transient protection has been achieved by immunizing mice with purified glycoproteins (2), the search for long-lasting immunity has led investigators to concentrate on the development of live vaccines which are better stimulators of T cells (7, 24, 27-29, 31, 36, 43). The use of live viruses such as vaccinia virus as vectors is controversial because of the toxicity of the parental strain itself (13, 21).

Experiments in mice have defined the requirements for induction of T-cell immunity to HSV. While purified proteins are capable of inducing excellent antibody responses (3), live virus was much more effective at inducing cell-mediated responses (9, 11, 27, 28, 37). Inactivation of virus by heat or UV light markedly reduces the ability of virus to induce HSV-specific cytotoxic T lymphocytes (CTL) (22). Schmid and Rouse demonstrated that the failure of inactivated HSV-1 (as opposed to live virus) to stimulate CTL activity (or increase precursor numbers) was due to an inability of these preparations to stimulate helper T cells (38).

Infection of cells by HSV leads to expression of a sequence of different virus-encoded proteins. The α (immediate-early) genes are expressed first (16, 36). The products of α genes are required for expression of the next set of genes, which are termed β (early) genes. The gene products of the β genes encode products required for DNA synthesis. Expression of the γ1 class of late genes can be detected before DNA replication, but the γ2 late gene products are barely detected in the absence of DNA replication (36).

Several viral proteins have been shown to regulate expression of HSV-1 genes. The ICP4 gene product is essential for β and γ protein expression (10). The ICP27 gene product is required for γ protein expression and viral DNA replication (26, 35). Separate functions of ICP27 activate γ1 and γ2 gene expression because the n504 mutant allows γ1 but not γ2 gene expression (35). The major DNA-binding protein (ICP8), a β product, is also an essential viral gene product because it is required for viral DNA replication (12, 32, 33) and late viral gene expression (12). Mutant viruses lacking ICP8 function express immediate-early and early viral gene products (12).

Although late glycoproteins of HSV are produced in great quantities in cell culture as a result of lytic infections and these proteins may be an important target of antiviral antibodies (3, 14, 18, 20), early regulatory proteins are also recognized by T cells (23, 25). Although T cells appear to be important in reactivation of herpesviruses, it is not clear what epitopes are seen in vivo. It is conceivable that proteins which are made in less quantity or at an earlier stage of infection may be more important in inducing T-cell immunity (23).

Live virus infection has been demonstrated to induce long-lived T-cell immunity. However, live virus vaccines, even those based on attenuated virus, are often shunned because of the possibility of (i) reversion to virulence or (ii) dissemination of even avirulent vaccines in unusual hosts (30). Therefore, we have examined the ability of live viruses that are unable to replicate to induce immune responses.

MATERIALS AND METHODS

Mice. Female BALB/c mice were purchased from Taconic Laboratory, Germantown, N.Y., and were used at 6 to 12 weeks of age. Mice were infected with virus (or medium alone) intraperitoneally (i.p.) in 0.5-ml volumes. In accordance with our Institutional Animal Care and Use Committee, in order to avoid 50% lethal dose measurements and the unnecessary sacrifice of animals, a previously established dose (5 × 10⁷ PFU of the mP strain of HSV-1) at which 80 to 100% of mice would die was used in these experiments (40).

Viruses. HSV-1 strains KOS 1.1 and mP were propagated on Vero cells as described previously (33). The ICP8 gene deletion mutant virus d301 was described previously (33) and was propagated and titrated on S-2 cells, which express the
ICP8 protein from a resident gene upon viral infection (33). The mutant viruses n504R has a nonsense mutation in the ICP27 gene and was described previously (35). This virus was propagated and titrated on V27 cells, which express the ICP27 protein from a resident gene upon HSV infection (35). The d301 and n504 mutants fail to replicate on Vero cells or other normal cells and thus are considered to be replication defective. They can, however, replicate on these special cells, which provide the complementing gene product. Wild-type virus gives very similar titers on Vero, S-2, or V27 cells. Thus, the administration of equal numbers of PFUs of these different viruses ensures that approximately similar numbers of viral particles are being administered, as observed previously (33, 35). The ICP4 gene deletion mutant virus d120 was a gift of Neal DeLuca (10). Vesicular stomatitis virus (VSV) (Indiana strain) was obtained from Robert Kauffman (Harvard Medical School) and was passaged on L cells as described previously (15). Virus stocks were stored at −70°C, and a new aliquot of stock virus was used for each experiment. UV-irradiated HSV-1 and UV-irradiated VSV were prepared by irradiating the virus at 0°C by using a 30-W UV source (Sigma; General Electric) for 45 min at a distance of 5 cm. Psoralen-inactivated virus was obtained from Lee Biomolecular (San Diego, Calif.). UV irradiation reduced viral titers by 5 to 6 log units, while psoralen-inactivated virus had no evidence of live virus when tested by plaque assay.

Assays of T-cell response. Immune spleen cells were obtained from mice injected i.p. 3 to 4 weeks earlier with 106 PFU of either the ICP4-, ICP27-, or ICP8-deficient HSV-1 mutant or the parental HSV-1 KOS 1.1 strain (virus titer was determined prior to inactivation in the case of inactivated viruses). Negative controls were phosphate-buffered saline (PBS)-injected mice. Spleen cells were depleted of erythrocytes and polymorphonuclear leukocytes by Ficoll-Hypaque gradient sedimentation. B cells were depleted by immunodepletion, using J-11d2 supernatants (6, 42). Splenocytes were incubated with J-11d2 supernatants for 30 min at 4°C and were then washed and further incubated with goat anti-rat antibody-coated latex-polymer beads with a magnetic core (Advanced Magnetics, Cambridge, Mass.). J11-d2-positive cells bound to the magnetic beads were then removed by a magnet (BioMag Separator; Advanced Magnetics). While decreasing the B cells background, this depletion did not eliminate all antigen-presenting cells, and good T-cell activity was seen (6). In experiments in which spleen cells were depleted of CD4+ cells, depletion was accomplished with the rat anti-mouse CD4 antibody GK1.5 (American Type Culture Collection). After depletion, the remaining spleen cells (now >98% T cells) were washed and incubated at 105 cells per well in quadruplicate in a total volume of 0.2 ml in 96-well round-bottom culture plates (Nunc, Roskilde, Denmark). Responder cells were stimulated with UV-irradiated HSV-1 KOS 1.1 or VSV. Control cultures without added viruses were prepared in parallel. Medium used was Dulbecco modified Eagle medium (Hazleton) supplemented with 5% bovine calf serum (HyClone Laboratories), heat inactivated at 56°C for 1 h, 100 U of penicillin (GIBCO) per ml, 100 μg of streptomycin per ml, 1 mM sodium pyruvate (GIBCO), 0.1 mM nonessential amino acids (GIBCO), 10−4 mM 2-mercaptoethanol (Sigma), and 2 mM glutamine (GIBCO). The cells were incubated for 3 or 5 days in a 10% CO2 at 37°C before being pulsed with 1 μCi of [3H]thymidine (New England Nuclear) for 6 h and harvested by using a Skatron cell harvester. The samples were counted for 1 min in a scintillation counter (Beta Trac 6895; TM Analytic).

Antibody assays. Serum samples were analyzed by enzyme-linked immunosorbent assay (ELISA) for the presence of HSV-specific antibodies. The protocol was adapted for murine serum from that described by Kahlen and Whitley (18). Microtiter plates (Linbro/Titer tek) were coated with 0.1 ml of a 1:50 dilution of a 102 PFU of HSV-1 (grown in Vero cells) in PBS overnight. Serum samples of mice immunized with viruses i.p. 3 weeks previously were obtained individually through retro-orbital bleeding. Microplates coated with HSV antigen were washed three times and incubated with 100 μl of serum diluted 1:100 and then threefold overnight at room temperature. Plates were then washed again and incubated with alkaline phosphatase-conjugated goat antimouse immunoglobulin G2a at a 1:250 dilution (Southern Biotechnology) for 3 h at 37°C. Thirty minutes after the addition of 1 mg of phosphatase substrate (Sigma 104) per ml, the reaction was stopped by the addition of 75 μl of 3 N NaOH. The plates were read with an ELISA reader at 405 nm. For all experiments, the standard was pooled serum from HSV-1-immunized mice. The negative control consisted of pooled naive mouse serum. Mouse sera were run individually, and data are presented as means and standard errors of the means.

RESULTS

Lack of morbidity with use of replication-defective viruses. The major DNA-binding protein, ICP8, is an essential viral gene product required for viral DNA replication. Similarly, ICP27 is an essential viral gene product required for late gene expression. To study the ability of replication-defective viruses to stimulate immunity, mice were injected with live HSV or replication-defective mutant viruses which were defective for either ICP8 (d301) or ICP27 (n504). Challenge of mice with up to 104 PFU of these replication-defective viruses had no apparent effect on the mice. Littersmates injected with 107 PFU of the parental KOS 1.1 strain were all killed.

Induction of antibody responses by replication-defective viruses. To determine whether the replication-defective viruses were capable of inducing antibody responses, we bled mice 2 weeks postchallenge and measured HSV-specific antibodies. Interestingly, the antibody responses, while present, were markedly lower than those seen after stimulation with parental (KOS 1.1) strain (Fig. 1). As expected, more antibody was induced by infection with the ICP27 mutant than by infection with the ICP8 mutant. Similar results were noted both 2 and 4 weeks postinfection in an independent experiment. To investigate whether expression of early (β) proteins was necessary for induction of antibody responses, we challenged mice with 106 PFU of a virus strain which could not produce either early or late proteins (the ICP4 deletion mutant d120). Challenge with the ICP4-deficient strain, while inducing a response greater than that seen with a medium control, was below that seen with the other mutants (Fig. 1). Antibody titers remained elevated in all groups for at least 3 months after immunization.

Induction of T-cell responses by replication-defective viruses. To investigate the ability of the various mutant viruses to induce T-cell immunity, we measured the responses of splenic T cells from challenged mice to viral antigens in vitro. Mice received 104 PFU of either live wild-type (KOS 1.1) virus or a replication-defective mutant (ICP4, ICP8, or ICP27). Three weeks later, T cells from mice of each group were incubated with UV-irradiated HSV. To control for the effect of nonspecific T-cell stimulation, we also evaluated the
responses to an unrelated virus, VSV. Splenic T cells from mice immunized with VSV did not proliferate in response to HSV (while the same cells did proliferate in response to VSV) (Fig. 2 and 3). Stimulation above the background level was seen in splenocytes from mice challenged with each of the replication-defective viruses (Fig. 2). While our results indicate that immunization of mice with the mutant viruses led to a level of stimulation less than that induced by the wild-type parental KOS 1.1 strain, evidence for substantial T-cell reactivity is seen with all replicative viruses. Similar responses were seen when spleen cells were stimulated for either 3 (Fig. 2) or 5 (Fig. 3) days in vitro. Previous experiments had indicated that no T-cell proliferation was obtained from T cells of mice immunized by heat-inactivated or UV-irradiated virus (30a, 39). Furthermore, immunization with psoralen-inactivated virus also did not stimulate T-cell responses (Fig. 3). The responding T cell was CD4 +, as in vitro depletion of spleen cells with anti-CD4 antibodies eliminated the response (Fig. 3).

Induction of protective immunity by replication-defective viruses. To assess the ability of replication-defective viruses to induce immunity to lethal HSV disease, we inoculated mice with 10 6 PFU of live ICP4-, ICP27-, or ICP8 mutant virus. Three to six weeks later (depending on the experiment), all mice were challenged with a lethal dose (5 × 10 7 PFU) of a virulent strain of HSV-1 (mp). In three separate experiments, all mice infected with 10 6 PFU of the ICP8 or ICP27 mutant were protected against lethal disease, while 80 to 100% of mock-infected mice died. To compare the protective effects of the various mutant viruses, subsequent experiments were performed with all three mutant viruses (d120, d301, and n504). While only one of nine control (PBS-injected) mice survived, survival with ICP27 or ICP8 mutant preimmunization was 100%. Even the ICP4 mutant (d120), which allows for expression of only the immediate-

DISCUSSION

The studies presented in this report demonstrate that replication-defective HSV mutant strains can induce both humoral and cellular immunity and protect against subsequent infection with wild-type virus. Cellular immunity is especially important in protection against infection by HSV, probably both in limiting virus spread at a site of productive infection and in maintaining virus in a latent infection (44). Thus, any agent which is capable of inducing anti-HSV cellular immunity is a potential anti-HSV vaccine. In contrast to the observations with replication-defective mutant viruses presented in this report, inactivated viruses are incapable of inducing cellular immunity to HSV (38). The replication-defective mutant viruses used in this study are intermediate in nature between an attenuated live virus (29) and an inactivated virus vaccine in that these mutant viruses can infect cells and carry out a substantial portion of the replicative cycle and thus are living, but they cannot produce progeny virus.

Studies with VSV have shown that immunization with defective interfering particles results in the generation of cellular immunity at levels less than that induced by whole virus (5). Defective interfering particles are able to stimulate CD4 + cells but not CD8 + cells, which may be important in T-cell immunity (5). Interestingly, immunization of swine with live VSV results in substantial levels of protective
immunity (34), suggesting that whole virus vaccines may be protective and that noninfectious particles may be suboptimal inducers of immunity.

The induction of cellular immunity by these mutant viruses is presumably due to the expression of viral gene products in the infected cells, processing of these viral polypeptides, and their subsequent presentation to helper T cells. The n504 ICP27 gene mutant virus appeared to elicit greater humoral and cellular immunity than did the d301 ICP8 gene mutant virus or the d120 ICP4 gene mutant virus. This finding is consistent with the ability of the n504 mutant virus to express nearly normal amounts of α, β, and γ1 late viral gene products (35), thereby expressing a wider range of viral gene products than does d301, which expresses α and β viral gene products and more limited amounts of γ viral gene products (12). The d120 mutant virus, which expresses the fewest number of viral gene products, elicited the lowest level of T-cell response.

The target for anti-HSV T-cell immunity is not well defined. The α ICP4 and ICP27 proteins are recognized by CTL from certain strains of mice (1, 23). Both mutant viruses express these gene products, and although n504 expresses a slightly truncated form of ICP27, this form of ICP27 should retain the potential CTL epitope identified by Banks et al. (1). Human CTL clones have been shown to recognize gD or gB (46). Murine T lymphocytes have been shown to recognize gB, gC, or gD (7, 17, 24, 27, 28, 37, 45). The n504 mutant should express more gD and gB than does the d301 mutant. Neither mutant is likely to express very significant levels of gC. Therefore, in general, the magnitude of the immune responses to these mutant viruses is consistent with the number of viral gene products expressed. This study suggests that the magnitude of the cellular immune response to HSV is proportional to the number of different viral gene products expressed by the infecting virus. This observation has implications for the design of vaccines against HSV.

None of the mutant viruses used in this study can replicate in cells that do not express the complementing viral gene product. Thus, it is unlikely that these viruses spread further than the initial cells that they infect. This consideration has two implications for the pathogenesis of these viruses. First, the viral antigens are expressed only in the cells that are initially infected, and these cells have to be capable of presenting the antigens for an immune response. Second, the viruses are not likely to spread to the nervous system. Consistent with this notion, no latent infection can be detected in studies using in situ hybridization to detect the latency-associated transcript in trigeminal ganglion tissue from animals inoculated with the mutant virus by corneal scarification (19a).

The fact that these replication-defective viruses are able to induce immune responses which are capable of protecting mice against lethal infection suggests a new general strategy for vaccine design. Many virus replicative cycles involve a programmed order of steps in viral replication in order to produce infectious progeny virus particles. If a regulatory gene mutation that allows expression of some or nearly all of the viral gene products but does not allow completion of the viral life cycle can be introduced into a viral genome,
immbity may be elicited against the viral gene products. The processing of the viral gene products should then allow the generation of a cellular immunity. However, the lack of spread of these viruses should provide a very safe vaccine. This approach should be applicable to any virus with a complex replicative cycle such as HSV.

ACKNOWLEDGMENTS

We thank Bernard Fields for helpful comments on the manuscript. D.M.K. was supported by grants CA26345 and AI20530. R.W.F. and L.H.N. were supported by grant AI20382.

REFERENCES


